Journals / MN Kardiyoloji / 2005 / Cilt: 12 - Sayı: 3

Serum lipids in diabetic cases: The effect of previous coronary events on lipid profile

Diyabetik olgularda serum lipidleri: Geçirilmiş koroner olayların lipid profiline etkisi

Pages
173–177
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The success rate of achieving the target levels of serum lipids was also higher in secondary prevention group but this not reached statistical significance except LDL-C.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: In our study we aimed to figure out that the success rate of primary and secondary prevention by evaluating the serum lipids in diabetic patients.
📊
Key Findings & Data:Material and Methods: 315 diabetic patients enrolled the study and divided into two groups by having coronary events and/or coronary interventions or not.
💡
Conclusion & Impact:The success rate of achieving the target levels of serum lipids was also higher in secondary prevention group but this not reached statistical significance except LDL-C.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Trigliseridler · Serum · Kolesterol

Abstract

Aim: In our study we aimed to figure out that the success rate of primary and secondary prevention by evaluating the serum lipids in diabetic patients. Material and Methods: 315 diabetic patients enrolled the study and divided into two groups by having coronary events and/or coronary interventions or not. The level of serum total cholesterol, LDL-C, HDL-C, trigliseride, and the rate of lipid-lowering drug usage were compared between groups. Results: Age, sex, frequency of hypertension, and smoking were not different between groups. The mean body mass index, the level of total cholesterol, LDL-C, and triglyceride were significantly lower in secondary prevention group compared to primary prevention group. In addition, the frequency of lipid-lowering drug usage was significantly higher in secondary prevention group. The difference of mean HDL-C level between the groups was not meaningful. Although the success rate to achieve the target level of serum LDL-C was significantly higher in secondary prevention group, the achievement of target levels were not statistically different between groups in relatıon to triglyceride and HDL-C. Conclusion: In diabetic cases, the frequency of lipid-lowering therapy was significantly higher in secondary prevention group compared to primary prevention group. The success rate of achieving the target levels of serum lipids was also higher in secondary prevention group but this not reached statistical significance except LDL-C.

Özet

Amaç: Çalışmamızda diyabetik olguların serum lipid profillerini inceleyerek primer ve sekonder korumada başarı düzeyini araştırmayı amaçladık. Gereç ve Yöntem: Çalışmaya 315 diyabetik olgu alındı ve olgular koroner olay ve/veya koroner girişim geçirenler ve geçirmeyenler olmak üzere iki gruba ayrıldı. Her iki grupta olguların serum total kolesterol, LDL-K, HDL-K, trigliserid seviyeleri tespit edildi ve lipid düşürücü ilaç kullanma oranları karşılaştırıldı. Bulgular: Her iki grup arasında yaş, cinsiyet, hipertansiyon ve sigara kullanma sıklığı açısından fark yoktu. Sekonder koruma grubunda primer koruma grubuna göre; ortalama beden kitle indeksi, total kolesterol, LDL-K, trigliserid seviyeleri önemli derecede düşükken, lipid düşürücü ilaç kullanım sıklığı belirgin olarak daha fazlaydı. Ortalama HDL-K seviyesi ise gruplar arasında farklı değildi. Hedef LDL-K değerine ulaşma başarısı sekonder koruma grubunda istatistiksel olarak belirgin şekilde yüksek iken, hedef trigliserid ve HDL-K değerine ulaşma başarısı açısından gruplar arası fark önemli değildi. Sonuç: Diyabetik olgularda lipid düşürücü tedavi kullanımı sekonder koruma grubunda anlamlı şekilde yüksektir. Hedef serum lipid değerlerine ulaşma başarısı sekonder koruma grubunda primer koruma grubuna göre yine daha yüksektir ancak bu yükseklik LDL-K dışında anlamlı düzeyde değildir.

🔖

Cite This Article

ÖZKAN, M., YOKUŞOĞLU, M., SAĞ, C., BAYSAN, O., HAŞİMİ, A., KÖZ, C., SAĞLAM, K., AZAL, Ö., UZUN, Ş., ERİNÇ, K., IŞIK, E. (2005). Serum lipids in diabetic cases: The effect of previous coronary events on lipid profile. MN Kardiyoloji, Cilt: 12 - Sayı: 3, 173–177. https://ajindex.com/articles/297564

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM. Pathogenesis of the atherosclerotic lesions: Imp­ lications for diabetes mellitus. Diabetes Care 1992; 5:1156-67
  2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes,other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16:434-44
  3. Kawate R, Yamakido M, Nishimoto Y, Bennett PH, Hamman RF, Knowler WC. Diabetes mellitus and its vascular comp-li-ca-ti-ons in Japanese migrants on the island of Hawaii. Diabetes Care 1979; 2:161-70
  4. Head J, Fuller JH. International variations in mortality among diabeic patients: The WHO Mutinational Study of Vascular Disease in Diabetics. Diabetologia 1990; 33:447-81
  5. Vigorita VJ, Morre GW, Hutchens GM. Absence of correlation between coronary arterial atherosclerosis and severity or duration of diabetes mellitus of adult onset. Am J Cardiol 1980; 46:535-42
  6. Waller BF, Palumbo PJ, Lie JT, Roberts WC. Status of the coronary arteries at necropsy in diabetes mellitus after age 30 years:Analysis of 229 diabetic patients with and without evidence of coronary heart disease and comparison to 183 control subjects. Am J Med 1980; 69:498-506
  7. Castelli WP. Making practical sense of clinical trials data in decreasing cardiovascular risk. Am J Cardiol 2001; 88:16-20
  8. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk in­ dividuals: a randomised placebo control trial Lancet 2002; 360:7-22
  9. Isles CG. Patients with acute coronary syndrome should start a statin while still in hospital. Heart. 2002; 88:5-6. 10.Norhammar A, Malmberg K, Ryden L, Tomvall P, Stenes trand U, Wallentin L; Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA) Un­ der utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myo- cardial infarction. Eur Heart J. 2003; 24:838-44. 11.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Re­port of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cho­ lesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97. 12.Grundy SM, Cleeman Jl, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Educatio